Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Abstract Inhaled therapeutics have high potential for the treatment of chronic respiratory diseases of high unmet medical need, such as idiopathic pulmonary fibrosis (IPF). Preclinical and early clinical evidence show that cellular communication network factor 2 (CCN2), previously called connective...

Full description

Saved in:
Bibliographic Details
Main Authors: Vanessa Neiens, Eva-Maria Hansbauer, Thomas J. Jaquin, Janet K. Peper-Gabriel, Poornima Mahavadi, Mark E. Snyder, Maximilian J. Grill, Cornelia Wurzenberger, Antonio Konitsiotis, Adriana Estrada-Bernal, Kristina Heinig, Athanasios Fysikopoulos, Nicolas Schwenck, Stefan Grüner, Denis Bartoschek, Theresia Mosebach, Sandra Kerstan, Joe Wrennall, Marleen Richter, Kentaro Noda, Konrad Hoetzenecker, Janette K. Burgess, Robert Tarran, Claudia Wurzenberger, Karl-Robert Wichmann, Jonas Biehler, Kei W. Müller, Andreas Guenther, Oliver Eickelberg, Mary F. Fitzgerald, Shane A. Olwill, Gabriele Matschiner, Marina Pavlidou
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-58568-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-58568-x

Similar Items